Previous Close | 1.1400 |
Open | 1.1500 |
Bid | 0.0000 x 2200 |
Ask | 0.0000 x 1400 |
Day's Range | 1.1350 - 1.2000 |
52 Week Range | 1.1300 - 3.5500 |
Volume | |
Avg. Volume | 347,464 |
Market Cap | 84.01M |
Beta (5Y Monthly) | 0.89 |
PE Ratio (TTM) | 12.78 |
EPS (TTM) | 0.0900 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.00 |
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2023 Earnings Call Transcript March 14, 2024 Protalix BioTherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03. Protalix BioTherapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, […]
PLX Sees Regulatory Approvals and Commercial Progress Amidst Financial Growth
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update.